. . "I, P(NT12130), P(NT12215), P(NT13190)" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "Zlat\u00FDm standardem l\u00E9\u010Dby pro pacienty s AL-amyloid\u00F3zou byla a\u017E do roku 2011 kombinace alkyla\u010Dn\u00EDho cytostatika (melfalanu \u010Di cyklofosfamidu)s dexametazonem. Pro vybran\u00E9 nemocn\u00E9 mlad\u0161\u00ED 65 let, s nevelk\u00FDm po\u0161kozen\u00EDm organizmu amyloidem a s dobrou srde\u010Dn\u00ED funkc\u00ED(EF > 40 %), je pova\u017Eov\u00E1na za optim\u00E1ln\u00ED vysokod\u00E1vkovan\u00E1 chemoterapie s autologn\u00ED transplantac\u00ED krvetvorn\u00FDch bun\u011Bk. U pacient\u016F s AL-amyloid\u00F3zou s n\u00EDzk\u00FDm po\u010Dtem plazmocyt\u016F v kostn\u00ED d\u0159eni se prov\u00E1d\u00ED sb\u011Br krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve a n\u00E1sledn\u00E1 vysokod\u00E1vkovan\u00E1 chemoterapie ihned po stanoven\u00ED diagn\u00F3zy. Na rozd\u00EDl od mnoho\u010Detn\u00E9ho myelomu nep\u0159edch\u00E1z\u00ED vysokod\u00E1vkovan\u00E9 chemoterapii n\u011Bkolikam\u011Bs\u00ED\u010Dn\u00ED konven\u010Dn\u00ED l\u00E9\u010Dba. V roce 2012 byly zve\u0159ejn\u011Bny rozs\u00E1hl\u00E9 zku\u0161enosti s nov\u00FDmi l\u00E9ky, kter\u00E9 byly pou\u017Eity pro l\u00E9\u010Dbu pacient\u016F s AL-amyloid\u00F3zou v r\u00E1mci klinick\u00FDch studi\u00ED f\u00E1ze I a II a ojedin\u011Ble i f\u00E1ze III." . "L\u00E9\u010Dba AL-amyloid\u00F3zy v roce 2012, p\u0159\u00EDnos nov\u00FDch l\u00E9k\u016F (bortezomibu, thalidomidu a lenalidomidu). P\u0159ehled publikovan\u00FDch klinick\u00FDch studi\u00ED" . . "14110" . "Adam, Zden\u011Bk" . "Zlat\u00FDm standardem l\u00E9\u010Dby pro pacienty s AL-amyloid\u00F3zou byla a\u017E do roku 2011 kombinace alkyla\u010Dn\u00EDho cytostatika (melfalanu \u010Di cyklofosfamidu)s dexametazonem. Pro vybran\u00E9 nemocn\u00E9 mlad\u0161\u00ED 65 let, s nevelk\u00FDm po\u0161kozen\u00EDm organizmu amyloidem a s dobrou srde\u010Dn\u00ED funkc\u00ED(EF > 40 %), je pova\u017Eov\u00E1na za optim\u00E1ln\u00ED vysokod\u00E1vkovan\u00E1 chemoterapie s autologn\u00ED transplantac\u00ED krvetvorn\u00FDch bun\u011Bk. U pacient\u016F s AL-amyloid\u00F3zou s n\u00EDzk\u00FDm po\u010Dtem plazmocyt\u016F v kostn\u00ED d\u0159eni se prov\u00E1d\u00ED sb\u011Br krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve a n\u00E1sledn\u00E1 vysokod\u00E1vkovan\u00E1 chemoterapie ihned po stanoven\u00ED diagn\u00F3zy. Na rozd\u00EDl od mnoho\u010Detn\u00E9ho myelomu nep\u0159edch\u00E1z\u00ED vysokod\u00E1vkovan\u00E9 chemoterapii n\u011Bkolikam\u011Bs\u00ED\u010Dn\u00ED konven\u010Dn\u00ED l\u00E9\u010Dba. V roce 2012 byly zve\u0159ejn\u011Bny rozs\u00E1hl\u00E9 zku\u0161enosti s nov\u00FDmi l\u00E9ky, kter\u00E9 byly pou\u017Eity pro l\u00E9\u010Dbu pacient\u016F s AL-amyloid\u00F3zou v r\u00E1mci klinick\u00FDch studi\u00ED f\u00E1ze I a II a ojedin\u011Ble i f\u00E1ze III."@cs . "Until 2011, the gold standard of treatment for patients with AL amyloidosis was the combination of alkylating cytostatics (melphalan or cyclophosphamide) and dexamethasone. For a selected group of patients under 65 years of age with only moderate damage to their body caused by amyloid and with good cardiac function (EF> 40%), high-dose chemotherapy with autologous hematopoietic cell transplantation seems to be optimal. Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed. In contrast to multiple myeloma, high-dose chemotherapy is not preceded by several months of conventional treatment. The year 2012 witnessed a release of reports about extensive experience with new drugs that were used in Phase I and Phase II clinical trials, and in isolated cases also in Phase III, for the treatment of patients with AL amyloidosis."@en . "L\u00E9\u010Dba AL-amyloid\u00F3zy v roce 2012, p\u0159\u00EDnos nov\u00FDch l\u00E9k\u016F (bortezomibu, thalidomidu a lenalidomidu). P\u0159ehled publikovan\u00FDch klinick\u00FDch studi\u00ED"@cs . . . "Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials"@en . . "6"^^ . "6"^^ . "CZ - \u010Cesk\u00E1 republika" . . "L\u00E9\u010Dba AL-amyloid\u00F3zy v roce 2012, p\u0159\u00EDnos nov\u00FDch l\u00E9k\u016F (bortezomibu, thalidomidu a lenalidomidu). P\u0159ehled publikovan\u00FDch klinick\u00FDch studi\u00ED"@cs . . . "84528" . . . "\u010D. 1" . . "RIV/00216224:14110/13:00065608" . "Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials"@en . . . . . "\u0160\u010Dudla, Vlastimil" . . . "Kr\u00E1l, Zden\u011Bk" . "ro\u010D. 59" . "AL amyloidosis; bortezomib; lenalidomide; thalidomide; high-dose chemotherapy with autologous transplantation"@en . "\u010Cerm\u00E1kov\u00E1, Zde\u0148ka" . "Krej\u010D\u00ED, Marta" . "0042-773X" . "L\u00E9\u010Dba AL-amyloid\u00F3zy v roce 2012, p\u0159\u00EDnos nov\u00FDch l\u00E9k\u016F (bortezomibu, thalidomidu a lenalidomidu). P\u0159ehled publikovan\u00FDch klinick\u00FDch studi\u00ED" . "Pour, Lud\u011Bk" . . . "[FD7ED08800F4]" . . . "27"^^ . . "RIV/00216224:14110/13:00065608!RIV14-MZ0-14110___" . . .